| Antigen-specific
IgG detected in sera from patients with prostate cancer and male
control blood donors.
| Antigen |
Antigen-specific
IgG Responses |
P-value a
(Odds ratio) |
| Patients
with Prostate Cancer |
Control
Male Blood Donors |
| MAD-CT-1 |
5/109 |
1/52 |
0.40 (2.45) |
| MAD-CT-2 |
3/109 |
0/52 |
0.23 (>4) |
| MAD-CT-3 |
2/109 |
0/52 |
0.33 (>2) |
| MAD-CT-4 |
3/109 |
1/52 |
0.75 (1.44) |
| MAD-CT-5 |
5/109 |
1/52 |
0.40 (2.45) |
| MAD-CT-6 |
4/109 |
2/52 |
0.96 (0.95) |
| MAD-CT-7 |
4/109 |
1/52 |
0.55 (1.94) |
a The proportion of patients with immunoreactivity to a specific antigen, versus reactivity in the control population, was tested for significance by chi-square analysis.
|
